FMP
Lifecore Biomedical, Inc.
LFCR
NASDAQ
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
6.72 USD
0.355 (5.29%)
Mr. Paul Josephs
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and pro...
0001005286
US5147661046
N/A
3515 Lyman Boulevard
952 368 4300
US
524
Feb 15, 1996
0001005286
NASDAQ
Drug Manufacturers -...
Healthcare
-
US5147661046
US
6.71
0.8
211.81k
248.62M
-
3.68-7.99
-6.52
-
-
-
-
-4.63
-
https://www.lifecore.com
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Tony Dante
Apr 4, 2025
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company operating in the medical, biomedical, and genetics industry. It focuses on developing and manufacturing products for the healthcare sector. Despite its strategic initiatives, LFCR faces challenges in meeting financial expectations, as evidenced by its recent earnings report. On April 3, 2025, LFCR reported an earnings per share (EPS) of -$0.47, which was below the estimated EPS of -$0.14. This represents a significant negative earnings surpri...
Rayan Ahmad
Apr 1, 2025
Lifecore Biomedical, Inc. (NASDAQ: LFCR) is a contract development and manufacturing organization. It specializes in providing integrated services to the pharmaceutical and medical device industries. As LFCR prepares to release its quarterly earnings on April 3, 2025, Wall Street anticipates an earnings per share loss of $0.14 and revenue of around $33.2 million. LFCR's financial results for the third quarter of fiscal year 2025 will be shared after the market closes. Following the release, the...
Andrew Wynn
Jan 8, 2025
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company involved in the development and manufacturing of biomaterials and medical devices. On January 8, 2025, Josephs Paul, the CEO and director, purchased 17,000 shares of LFCR at $5.74 per share. This acquisition increased his total holdings to 559,717 shares, indicating his confidence in the company's future. Despite this insider purchase, LFCR is currently under investigation by Bronstein, Gewirtz & Grossman, LLC. The firm is examining potential...
Tony Dante
Jan 2, 2025
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company that operates in the biomedical sector, focusing on the development and manufacturing of complex medical products. It competes with other firms in the industry by leveraging its expertise in biopolymer and pharmaceutical-grade manufacturing. LFCR's recent financial performance provides insights into its current market position and future potential. On January 2, 2025, LFCR reported an earnings per share (EPS) of -$0.2015, surpassing the estim...
Andrew Wynn
Dec 26, 2024
Lifecore Biomedical, Inc. (NASDAQ: LFCR) is preparing to release its quarterly earnings on January 2, 2025. As a fully integrated contract development and manufacturing organization, LFCR plays a significant role in the biomedical sector. Wall Street anticipates an earnings per share (EPS) loss of $0.27, with projected revenue of around $29.7 million. LFCR's financial metrics provide a deeper understanding of its market position. The company has a price-to-earnings (P/E) ratio of 35.87, indicat...
Zacks Investment Research
Mar 21, 2024
Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.
Zacks Investment Research
Feb 6, 2024
Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research
Sep 28, 2023
Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.